Elevated expression of platelet-derived chemokines in patients with antiphospholipid syndrome

Journal of Autoimmunity

Volumn 65, Issue , 2015, Pages 30-37

  Patsouras, Markos D ^a   Sikara, Marina P ^a   Grika, Eleftheria P ^a   Moutsopoulos, Haralampos M ^a   Tzioufas, Athanasios G ^a   Vlachoyiannopoulos, Panayiotis G ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Antiphospholipid syndrome; CCL5; CXCL4; CXCL4L1; CXCL7; Platelet derived chemokines

Indexed keywords

CHEMOKINE; CXCL4 CHEMOKINE; CXCL4L1 CHEMOKINE; CXCL7 CHEMOKINE; IMMUNOGLOBULIN G ANTIBODY; MESSENGER RNA; RANTES; UNCLASSIFIED DRUG; BETA THROMBOGLOBULIN; BETA2 GLYCOPROTEIN 1; BIOLOGICAL MARKER; CCL5 PROTEIN, HUMAN; PF4V1 PROTEIN, HUMAN; PPBP PROTEIN, HUMAN; THROMBOCYTE FACTOR 4;

ANTIPHOSPHOLIPID SYNDROME; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTE; ALLELE; BLOOD; CHEMOTAXIS; CORONARY ARTERY DISEASE; FEMALE; IMMUNOLOGY; METABOLISM; THROMBOCYTE ACTIVATION;

ALLELES; ANTIPHOSPHOLIPID SYNDROME; BETA 2-GLYCOPROTEIN I; BETA-THROMBOGLOBULIN; BIOMARKERS; BLOOD PLATELETS; CHEMOKINE CCL5; CHEMOKINES; CHEMOTAXIS; CORONARY ARTERY DISEASE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; PLATELET ACTIVATION; PLATELET FACTOR 4; REAL-TIME POLYMERASE CHAIN REACTION;

EID: 84939179715     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2015.08.001     Document Type: Article

References (50)

1. Miyakis S., Lockshin M.D., Atsumi T., Branch D.W., Brey R.L., Cervera R., et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J. Thromb. Haemost. 2006, 4:295-306.
2. Cervera R., Piette J.C., Font J., Khamashta M.A., Shoenfeld Y., Camps M.T., et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum. 2002, 46:1019-1027.
3. Hernandez-Molina G., Espericueta-Arriola G., Cabral A.R. The role of lupus anticoagulant and triple marker positivity as risk factors for rethrombosis in patients with primary antiphospholipid syndrome. Clin. Exp. Rheumatol. 2013, 31:382-388.
4. Fischetti F., Durigutto P., Pellis V., Debeus A., Macor P., Bulla R., et al. Thrombus formation induced by antibodies to beta2-glycoprotein I is complement dependent and requires a priming factor. Blood 2005, 106:2340-2346.
5. Arad A., Proulle V., Furie R.A., Furie B.C., Furie B. beta(2)-Glycoprotein-1 autoantibodies from patients with antiphospholipid syndrome are sufficient to potentiate arterial thrombus formation in a mouse model. Blood 2011, 117:3453-3459.
6. Ioannou Y., Zhang J.Y., Qi M., Gao L., Qi J.C., Yu D.M., et al. Novel assays of thrombogenic pathogenicity in the antiphospholipid syndrome based on the detection of molecular oxidative modification of the major autoantigen beta2-glycoprotein I. Arthritis Rheum. 2011, 63:2774-2782.
7. Ioannou Y., Zhang J.Y., Passam F.H., Rahgozar S., Qi J.C., Giannakopoulos B., et al. Naturally occurring free thiols within beta 2-glycoprotein I in vivo: nitrosylation, redox modification by endothelial cells, and regulation of oxidative stress-induced cell injury. Blood 2010, 116:1961-1970.
8. Allen K.L., Fonseca F.V., Betapudi V., Willard B., Zhang J., McCrae K.R. A novel pathway for human endothelial cell activation by antiphospholipid/anti-beta2 glycoprotein I antibodies. Blood 2012, 119:884-893.
9. Lambrianides A., Carroll C.J., Pierangeli S.S., Pericleous C., Branch W., Rice J., et al. Effects of polyclonal IgG derived from patients with different clinical types of the antiphospholipid syndrome on monocyte signaling pathways. J. Immunol. 2010, 184:6622-6628.
10. Pierangeli S.S., Vega-Ostertag M.E., Raschi E., Liu X., Romay-Penabad Z., De Micheli V., et al. Toll-like receptor and antiphospholipid mediated thrombosis: in vivo studies. Ann. Rheum. Dis. 2007, 66:1327-1333.
11. Romay-Penabad Z., Montiel-Manzano M.G., Shilagard T., Papalardo E., Vargas G., Deora A.B., et al. Annexin A2 is involved in antiphospholipid antibody-mediated pathogenic effects in vitro and in vivo. Blood 2009, 114:3074-3083.
12. Shi T., Giannakopoulos B., Yan X., Yu P., Berndt M.C., Andrews R.K., et al. Anti-beta2-glycoprotein I antibodies in complex with beta2-glycoprotein I can activate platelets in a dysregulated manner via glycoprotein Ib-IX-V. Arthritis Rheum. 2006, 54:2558-2567.
13. Urbanus R.T., Pennings M.T., Derksen R.H., de Groot P.G. Platelet activation by dimeric beta2-glycoprotein I requires signaling via both glycoprotein Ibalpha and apolipoprotein E receptor 2'. J. Thromb. Haemost. 2008, 6:1405-1412.
14. Sikara M.P., Routsias J.G., Samiotaki M., Panayotou G., Moutsopoulos H.M., Vlachoyiannopoulos P.G. β2 Glycoprotein I (β2GPI) binds platelet factor 4 (PF4): implications for the pathogenesis of antiphospholipid syndrome. Blood 2010, 115:713-723.
15. Pierangeli S.S., Girardi G., Vega-Ostertag M., Liu X., Espinola R.G., Salmon J. Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia. Arthritis Rheum. 2005, 52:2120-2124.
16. Meroni P.L., Borghi M.O., Raschi E., Tedesco F. Pathogenesis of antiphospholipid syndrome: understanding the antibodies. Nat. Rev. Rheumatol. 2011, 7:330-339.
17. van Bon L., Affandi A.J., Broen J., Christmann R.B., Marijnissen R.J., Stawski L., et al. Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis. N. Engl. J. Med. 2014, 370:433-443.
18. Struyf S., Burdick M.D., Proost P., Van Damme J., Strieter R.M. Platelets release CXCL4L1, a nonallelic variant of the chemokine platelet factor-4/CXCL4 and potent inhibitor of angiogenesis. Circ. Res. 2004, 95:855-857.
19. Green C.J., Charles R.S., Edwards B.F., Johnson P.H. Identification and characterization of PF4varl, a human gene variant of platelet factor 4. Mol. Cell Biol. 1989, 9:1445-1451.
20. Dubrac A., Quemener C., Lacazette E., Lopez F., Zanibellato C., Wu W.G., et al. Functional divergence between 2 chemokines is conferred by single amino acid change. Blood 2010, 116:4703-4711.
21. Eslin D.E., Zhang C., Samuels K.J., Rauova L., Zhai L., Niewiarowski S., et al. Transgenic mice studies demonstrate a role for platelet factor 4 in thrombosis: dissociation between anticoagulant and antithrombotic effect of heparin. Blood 2004, 104:3173-3180.
22. Lambert M.P., Sachais B.S., Kowalska M.A. Chemokines and thrombogenicity. Thromb. Haemost. 2007, 97:722-729.
23. Kasper B., Brandt E., Brandau S., Petersen F. Platelet factor 4 (CXC chemokine ligand 4) differentially regulates respiratory burst, survival, and cytokine expression of human monocytes by using distinct signaling pathways. J. Immunol. 2007, 179:2584-2591.
24. Nassar T., Sachais B.S., Akkawi S., Kowalska M.A., Bdeir K., Leitersdorf E., et al. Platelet factor 4 enhances the binding of oxidized low-density lipoprotein to vascular wall cells. J. Biol. Chem. 2003, 278:6187-6193.
25. Aidoudi S., Bikfalvi A. Interaction of PF4 (CXCL4) with the vasculature: a role in atherosclerosis and angiogenesis. Thromb. Haemost. 2010, 104:941-948.
26. Yang L., Du J., Hou J., Jiang H., Zou J. Platelet factor-4 and its p17-70 peptide inhibit myeloma proliferation and angiogenesis in vivo. BMC Cancer 2011, 11:261.
27. Schulze A., Jensch I., Krauel K., Alahmad A., Muller H.P., Greinacher A., et al. New insights in heparin-induced thrombocytopenia by the use of fluid-phase assays to detect specifically platelet factor 4/heparin complex antibodies and antibody-secreting cells. Thromb. Res. 2014, 134:174-181.
28. Van Raemdonck K., Gouwy M., Lepers S.A., Van Damme J., Struyf S. CXCL4L1 and CXCL4 signaling in human lymphatic and microvascular endothelial cells and activated lymphocytes: involvement of mitogen-activated protein (MAP) kinases, Src and p70S6 kinase. Angiogenesis 2014, 17:631-640.
29. Struyf S., Salogni L., Burdick M.D., Vandercappellen J., Gouwy M., Noppen S., et al. Angiostatic and chemotactic activities of the CXC chemokine CXCL4L1 (platelet factor-4 variant) are mediated by CXCR3. Blood 2011, 117:480-488.
30. Lasagni L., Grepin R., Mazzinghi B., Lazzeri E., Meini C., Sagrinati C., et al. PF-4/CXCL4 and CXCL4L1 exhibit distinct subcellular localization and a differentially regulated mechanism of secretion. Blood 2007, 109:4127-4134.
31. von Hundelshausen P., Petersen F., Brandt E. Platelet-derived chemokines in vascular biology. Thromb. Haemost. 2007, 97:704-713.
32. Laubli H., Spanaus K.S., Borsig L. Selectin-mediated activation of endothelial cells induces expression of CCL5 and promotes metastasis through recruitment of monocytes. Blood 2009, 114:4583-4591.
33. Schall T.J., Jongstra J., Dyer B.J., Jorgensen J., Clayberger C., Davis M.M., et al. A human T cell-specific molecule is a member of a new gene family. 1988. J. Immunol. 2009, 182:3947-3954.
34. Weeterings C., Adelmeijer J., Myles T., de Groot P.G., Lisman T. Glycoprotein Ibalpha-mediated platelet adhesion and aggregation to immobilized thrombin under conditions of flow. Arterioscler. Thromb. Vasc. Biol. 2006, 26:670-675.
35. Amisten S. A rapid and efficient platelet purification protocol for platelet gene expression studies. Methods Mol. Biol. 2012, 788:155-172.
36. Di Simone N., Di Nicuolo F., D'Ippolito S., Castellani R., Tersigni C., Caruso A., et al. Antiphospholipid antibodies affect human endometrial angiogenesis. Biol. Reprod. 2010, 83:212-219.
37. Di Simone N., D'Ippolito S., Marana R., Di Nicuolo F., Castellani R., Pierangeli S.S., et al. Antiphospholipid antibodies affect human endometrial angiogenesis: protective effect of a synthetic peptide (TIFI) mimicking the phospholipid binding site of beta(2) glycoprotein I. Am. J. Reprod. Immunol. 2013, 70:299-308.
38. Vandercappellen J., Liekens S., Bronckaers A., Noppen S., Ronsse I., Dillen C., et al. The COOH-terminal peptide of platelet factor-4 variant (CXCL4L1/PF-4var47-70) strongly inhibits angiogenesis and suppresses B16 melanoma growth in vivo. Mol. Cancer Res. 2010, 8:322-334.
39. Sarabi A., Kramp B.K., Drechsler M., Hackeng T.M., Soehnlein O., Weber C., et al. CXCL4L1 inhibits angiogenesis and induces undirected endothelial cell migration without affecting endothelial cell proliferation and monocyte recruitment. J. Thromb. Haemost. 2011, 9:209-219.
40. Kuo J.H., Chen Y.P., Liu J.S., Dubrac A., Quemener C., Prats H., et al. Alternative C-terminal helix orientation alters chemokine function: structure of the anti-angiogenic chemokine, CXCL4L1. J. Biol. Chem. 2013, 288:13522-13533.
41. Pengo V., Banzato A., Denas G., Jose S.P., Bison E., Hoxha A., et al. Correct laboratory approach to APS diagnosis and monitoring. Autoimmun. Rev. 2013, 12:832-834.
42. De Sutter J., Van de Veire N.R., Struyf S., Philippe J., De Buyzere M., Van Damme J. PF-4var/CXCL4L1 predicts outcome in stable coronary artery disease patients with preserved left ventricular function. PLoS One 2012, 7:e31343.
43. Broder A., Chan J.J., Putterman C. Dendritic cells: an important link between antiphospholipid antibodies, endothelial dysfunction, and atherosclerosis in autoimmune and non-autoimmune diseases. Clin. Immunol. 2013, 146:197-206.
44. Vlachoyiannopoulos P.G., Kanellopoulos P.G., Ioannidis J.P., Tektonidou M.G., Mastorakou I., Moutsopoulos H.M. Atherosclerosis in premenopausal women with antiphospholipid syndrome and systemic lupus erythematosus: a controlled study. Rheumatol. (Oxford) 2003, 42:645-651.
45. Nesmelova I.V., Sham Y., Gao J., Mayo K.H. CXC and CC chemokines form mixed heterodimers: association free energies from molecular dynamics simulations and experimental correlations. J. Biol. Chem. 2008, 283:24155-24166.
46. Koenen R.R., von Hundelshausen P., Nesmelova I.V., Zernecke A., Liehn E.A., Sarabi A., et al. Disrupting functional interactions between platelet chemokines inhibits atherosclerosis in hyperlipidemic mice. Nat. Med. 2009, 15:97-103.
47. Pervushina O., Scheuerer B., Reiling N., Behnke L., Schroder J.M., Kasper B., et al. Platelet factor 4/CXCL4 induces phagocytosis and the generation of reactive oxygen metabolites in mononuclear phagocytes independently of Gi protein activation or intracellular calcium transients. J. Immunol. 2004, 173:2060-2067.
48. Scheuerer B., Ernst M., Durrbaum-Landmann I., Fleischer J., Grage-Griebenow E., Brandt E., et al. The CXC-chemokine platelet factor 4 promotes monocyte survival and induces monocyte differentiation into macrophages. Blood 2000, 95:1158-1166.
49. Billstrom Schroeder M., Worthen G.S. Viral regulation of RANTES expression during human cytomegalovirus infection of endothelial cells. J. Virol. 2001, 75:3383-3390.
50. Szabo M.C., Butcher E.C., McIntyre B.W., Schall T.J., Bacon K.B. RANTES stimulation of T lymphocyte adhesion and activation: role for LFA-1 and ICAM-3. Eur. J. Immunol. 1997, 27:1061-1068.